omega-n-methylarginine has been researched along with spironolactone in 1 studies
| Studies (omega-n-methylarginine) | Trials (omega-n-methylarginine) | Recent Studies (post-2010) (omega-n-methylarginine) | Studies (spironolactone) | Trials (spironolactone) | Recent Studies (post-2010) (spironolactone) |
|---|---|---|---|---|---|
| 4,411 | 344 | 336 | 7,222 | 960 | 1,923 |
| Protein | Taxonomy | omega-n-methylarginine (IC50) | spironolactone (IC50) |
|---|---|---|---|
| Chain A, Mineralocorticoid receptor | Homo sapiens (human) | 0.049 | |
| Chain A, Mineralocorticoid receptor | Homo sapiens (human) | 0.049 | |
| Estrogen receptor | Homo sapiens (human) | 5.702 | |
| Glucocorticoid receptor | Homo sapiens (human) | 4.0745 | |
| Progesterone receptor | Homo sapiens (human) | 1.675 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 1.9025 | |
| Mineralocorticoid receptor | Homo sapiens (human) | 0.0315 | |
| Androgen receptor | Homo sapiens (human) | 0.3585 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.406 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 1.9025 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 1.9025 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 1.9025 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 6.92 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farquharson, CA; Struthers, AD | 1 |
1 trial(s) available for omega-n-methylarginine and spironolactone
| Article | Year |
|---|---|
Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.
Topics: Aged; Angiotensin I; Angiotensin II; Chronic Disease; Cross-Over Studies; Diuretics; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Forearm; Heart Failure; Humans; Male; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Spironolactone; Vasodilation | 2000 |